Site Search
Displaying results 21 - 30 of 573
Resource | Publications,
This report aims to provide countries and suppliers with estimates of the global market for antiretroviral (ARV) medicines in low- and middle-income countries for 2020-2024. It includes estimates of the global demand for active pharmaceutical ingredients (APIs) and ARVs for adults receiving first-line ART to enable suppliers to plan and manage their manufacturing capacities accordingly.
Resource | Publications,
Multiple agencies and actors have voiced their concerns around the exclusion of pregnant women from clinical trials and the associated harm and risks of these policies. More recently, the importance of allowing pregnant women the opportunity to take part in clinical trials has received renewed attention during the COVID-19 pandemic.
Recognizing the urgency of addressing this issue, the IMPAACT Network and WHO held a workshop to refine optimal approaches to studying the safety and efficacy of new HIV-related drugs during pregnancy and to establish the next steps for creating materials and methods that would support the implementation of such studies.
Resource | Publications,
HIV drug resistance (HIVDR) can compromise the effectiveness of antiretroviral therapy (ART) in reducing HIV incidence and HIV-associated morbidity and mortality. Minimizing the spread of HIVDR is a critical aspect of the broader global response to antimicrobial resistance.
WHO recommends that countries routinely implement nationally representative HIVDR surveys. The WHO HIV drug resistance report 2021 shows substantial progress in the implementation of HIVDR surveillance. Between 2014 and 2021, 56 countries implemented HIVDR surveys using WHO-recommended methods. The HIV drug resistance report 2021 summarizes findings from 38 countries that had finalized the surveys by the time of this report and shared data with WHO.
Resource | Guidelines,
This global progress in identification of newer drug molecules that are more robust and less toxic, a significant reduction in the cost of therapy and innovative approaches to service delivery and increasing access to treatment have literally transformed the disease from a virtual death sentence in the early 1980s to a chronic manageable disease now.
Resource | Publications,
The United Nations Sustainable Development Cooperation Framework (“Cooperation Framework”) is an agreement between the UN and the host government and determines a country’s development priorities as well as the UN development system’s contributions to them. As AMR hinders progress in many of the Sustainable Development Goals (SDGs), coordinated action across UN organizations and government agencies is needed to effectively tackle AMR across all sectors. A new guidance for UN country teams builds the case for AMR as a development issue and component of broader issues such as One Health, UHC and health security, food systems and planetary health: it aims to establish AMR as a higher priority on the policy and development agenda; stimulate multi-stakeholder interest; and attract funding.
Resource | Publications,
In 2015, to advance the global and national response to antimicrobial resistance (AMR), the World Health Assembly issued resolution WHA68.7 calling for all Member States to develop AMR national action plans that address the five objectives of the World Health Organization Global Action Plan (GAP) by May 2017. The WHO GAP provides a framework to support countries in developing their national action plans on AMR. To operationalize and accelerate implementation of national action plans on AMR, WHO has developed a costing and budgeting tool and accompanying user guide. The purpose is to support countries in costing prioritized activities of an operational plan linked to their AMR national action plan, and identify existing funding and funding gaps to promote resource mobilization and sustainable implementation. The target audience of the publication are national policy makers and designated costing coordinators for national action plans on AMR.
Resource | Publications,
WHO’s antiretroviral treatment (ART) clinic-based acquired drug resistance survey method yields robust estimates of HIV viral suppression and acquired HIV drug resistance in adults, children and adolescents taking both dolutegravir and non-dolutegravir based regimens.
Results are used to inform ART programme decision making regarding optimal ART regimens and support evaluation of programme quality with respect to maximizing viral load suppression and minimizing emergence of resistance in people taking ART.
Resource | Publications,
During initial days of COVID pandemic, HIV infection was not considered as a risk factor for COVID-19 or more severe disease. However, recent studies conducted in larger samples suggest that PLHIV (particularly with low CD4 counts or not under ART) if infected with COVID are more likely to have severe clinical course in comparison to HIV negatives (Ambrosioni et al 2021).
Moreover, the COVID-19 pandemic has hugely disrupted HIV prevention and treatment services globally and created challenges to continue the essential service delivery. A recent modelling study suggests that in sub-Saharan Africa a 6-month interruption of ART would result in an excess of 500 000 adult deaths from HIV infection during a 4-year period and an up to twofold increase in mother-to-child transmission of HIV.
Resource | Publications,
NCASC published second edition of user manual for HIV Care and ART Tracking (DHIS2 Tracker, mHealth and Biometric) System. This updated manual covers the series of changes made within the system after user feedback, developers changes, updates of the National Guidelines so that this will help all the technical staff (Clinicians, HIV Focal Person, Medical Recorder, HIV/ART Counselor and Data Capturer) of the HTC and ART centers of various non-government and government organizations to keep records and make reports of HIV-related services based on recommended format of iHMIS.